TEVA-MEDROXYPROGESTERONE TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
26-02-2015
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
MEDROXYPROGESTERONE ACETATE
Beschikbaar vanaf:
TEVA CANADA LIMITED
ATC-code:
G03DA02
INN (Algemene Internationale Benaming):
MEDROXYPROGESTERONE
Dosering:
5MG
farmaceutische vorm:
TABLET
Samenstelling:
MEDROXYPROGESTERONE ACETATE 5MG
Toedieningsweg:
ORAL
Eenheden in pakket:
100/500/1000
Prescription-type:
Prescription
Therapeutisch gebied:
PROGESTINS
Product samenvatting:
Active ingredient group (AIG) number: 0106339005; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2011-01-18
Productkenmerken
PRODUCT MONOGRAPH
PR
TEVA-MEDROXYPROGESTERONE
medroxyprogesterone acetate tablets USP
2.5 mg, 5 mg and 10 mg
PROGESTIN
Teva Canada Limited
Date of Revision:
30 Novopharm Court
May 12, 2014
Toronto, Ontario
M1B 2K9
Control No: 173232
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
14
DRUG INTERACTIONS
..........................................................................................................
16
DOSAGE AND ADMINISTRATION
......................................................................................
18
OVERDOSAGE
........................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
21
STORAGE AND STABILITY
.................................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 24
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
.................................................................................
25
CLINICAL
TRIALS..................................................................................................................
26
DETAILED PHARMACOLOGY
.............................................................................................
28
TOXICOLOGY
..............
Lees het volledige document
